Diurnal Group plc operates as a specialty pharma company. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Its product pipeline includes Infacort for use in children suffering from adrenal insufficiency; and Chronocort, which completed Phase III clinical trials targeting congenital adrenal hyperplasia in adult patients, as well as adrenal insufficiency.
Read More…
(Ad)
Each week, an exclusive group of investors receives access to a simple list of 3 stocks to put on their radar for the week ahead.
You can sign up today to receive access to next week's watchlist -- generated by a proprietary methodology -- at no cost or obligation.
